deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT03239106

A Study Examining the Medication Apremilast as Treatment for Chronic Itch

An Open Label Study of Apremilast in Chronic Idiopathic Pruritus

Sponsor: Celgene Corporation

Conditions Itch
Interventions Apremilast
Updated 16 times since 2017 Last updated: Jun 23, 2021 Started: Dec 1, 2017 Primary completion: Oct 31, 2018 Completion: Sep 19, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Itch and is currently completed. Celgene Corporation leads this study, which shows 16 recorded versions since 2017 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Aug 2017 – ~Jun 2018 · 10 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Nov 2018 · 4 months · monthly snapshot~Nov 2018 – ~Jun 2019 · 7 months · monthly snapshot~Jun 2019 – ~Oct 2019 · 4 months · monthly snapshot~Oct 2019 – ~May 2020 · 7 months · monthly snapshot~May 2020 – ~Nov 2020 · 6 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Dec 2021 · 3 months · monthly snapshot~Dec 2021 – ~Dec 2022 · 12 months · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Jul 2024 · 18 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

16 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Jan 2023 — Jul 2024 [monthly]

    Completed PHASE2

  5. Dec 2022 — Jan 2023 [monthly]

    Completed PHASE2

▶ Show 11 earlier versions

  1. Dec 2021 — Dec 2022 [monthly]

    Completed PHASE2

  2. Sep 2021 — Dec 2021 [monthly]

    Completed PHASE2

  3. Jan 2021 — Sep 2021 [monthly]

    Completed PHASE2

  4. Nov 2020 — Jan 2021 [monthly]

    Completed PHASE2

  5. May 2020 — Nov 2020 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  6. Oct 2019 — May 2020 [monthly]

    Active Not Recruiting PHASE2

  7. Jun 2019 — Oct 2019 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  8. Nov 2018 — Jun 2019 [monthly]

    Recruiting PHASE2

  9. Jul 2018 — Nov 2018 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  10. Jun 2018 — Jul 2018 [monthly]

    Not Yet Recruiting PHASE2

  11. Aug 2017 — Jun 2018 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Celgene Corporation
  • Washington University School of Medicine
Data source: Washington University School of Medicine

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations